The American College of Gastroenterology (ACG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ACG, as an ACCME accredited provider, ensures balance, independence, objectivity, and scientific rigor in all of its directly and jointly provided education activities. All who are in a position to control the content of an education activity (including their spouse or partner) are required to disclose to ACG all relevant financial relationships in any amount occurring in the past 12 months with any commercial interest that may create a conflict of interest related to the subject matter of an education activity. Safeguards against commercial bias have been put in place by ACG. Anyone who refuses to disclose relevant financial relationships will be disqualified. ACG ensures any conflicts of interest are resolved before the educational activity occurs and discloses all relevant financial relationships to the learners prior to the beginning of an education activity.
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, consumed by, or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Relevant Financial Relationships
The ACCME defines ‘relevant’ financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The ACCME has not set a minimum dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME considers financial relationships to create actual conflicts of interest in CME when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The vast majority of the material presented in the ACG Education Universe has previously been presented in lecture or other learning format, and author disclosure information reflects the content and format for disclosure provided by the presenter as of the date that his/her material was presented and captured electronically, and in compliance with ACG policies and ACCME requirements in effect as of that date of presentation. Author and planner conflicts were identified and resolved in accordance with ACG’s Policies and Procedures on Identifying and Resolving Conflicts of Interest.
Unapproved 'Off-Label' Usage Policy
If any unapproved or off-label use of a product is to be referenced in a CME program presentation, the faculty member shall be required to disclose that the product is either investigational or it is not labeled for the usage being discussed.
Geoffrey L. Braden, MD, FACG
Advisory Board: Medscape Gastroenterology
Consultant: Janssen Biotech (Remicade)
Speaker's Bureau: AbbVie, Janssen Biotech
Brooks D. Cash, MD, FACG
Consultant: Allergan, Daichi Sankyo, Ironwood, Paion, Salix, Sebela, Synergy, Torax
Speaker's Bureau: Allergan, Daichi, Sankyo, Salix
Silvio W. de Melo, Jr., MD
Dr. de Melo has indicated no relevant financial relationships.
Kenneth R. DeVault, MD, FACG
Board of Directors: Mayo Clinic
Consultant: Ironwood, Salix
Research Grant: Takeda
Seth A. Gross, MD, FACG
Consultant: Check-Cap, Cook, Medivators
Speaker's Bureau: CDX Diagnostics, Olympus
Stockholder: CSA Medical
Philip O. Katz, MD, FACG
Board of Directors: Esophageal Cancer Action Network
Consultant: Pfizer Consumer, Torax
Speaker's Bureau: Medtronic
Jami A.R. Kinnucan, MD
Advisory Board: AbbVie
Christina C. Lindenmeyer, MD
Dr. Lindenmeyer has indicated no relevant financial relationships.
Ryan D. Madanick, MD
Other: Director AGA Academy of Educators
Rajiv T. Majithia, MD, FACG
Speaker's Bureau: Gilead
Lisa B. Malter, MD, FACG
Dr. Malter has indicated no relevant financial relationships.
Mark C. Mattar, MD, FACG
Speaker's Bureau: AbbVie
Adam E. Mikolajczyk, MD
Dr. Mikolajczyk has indicated no relevant financial relationships.
Neha Nigam, MD
Dr. Nigam has indicated no relevant financial relationships.
Inessa Normatov, MD
Dr. Normatov has indicated no relevant financial relationships.
Amit Patel, MD
Dr. Patel has indicated no relevant financial relationships.
Anjana A. Pillai, MD
Speaker's Bureau: Simply Speaking (sponsored by Gilead)
Kamron Pourmand, MD
Dr. Pourmand has indicated no relevant financial relationships.
Francisco C. Ramirez, MD, FACG
Dr. Ramirez has indicated no relevant financial relationships.
Zeeshan Ramzan, MD, FACG
Dr. Ramzan has indicated no relevant financial relationships.
Mona Rezapour, MD
Dr. Rezapour has indicated no relevant financial relationships.
David T. Rubin, MD, FACG
Advisory Board: CCFA
Consultant: AbbVie Pharmaceuticals, Amgen, Emmi, Genentech, Janssen, Pfizer, Shire, Takeda, UCB Pharma
Employee: Cornerstones Health Inc/Non-Profit, GoDuRn LLC
Research Grant: AbbVie, Genentech, Janssen, Prometheus Laboratories, Shire, Takeda, UCB
Royalties: Slack Publications
Neeral L. Shah, MD
Advisory Board: Gilead
Mitchell L. Shiffman, MD, FACG
Advisory Board: AbbVie, Bristol-Myers Squibb, Gilead, Intercept, Merck, Salix
Research Grant: AbbVie, Bristol-Myers Squibb, Conatus, Cyma Bay, Galactin, Gilead, Immuron, Intercept, Merck, NGMBio, Novartis, Shire
Speaker's Bureau: AbbVie, Bristol-Myers Squibb, Gilead, Intercept, Merck
Mark Anthony Sofia, MD
Consultant: Janssen Biotech Inc.
Kaartik Soota, MD
Dr. Soota has indicated no relevant financial relationships.
Matthew J. Stotts, MD
Dr. Stotts has indicated no relevant financial relationships.
Betty J. White, ARNP
Speaker's Bureau: AbbVie, Janssen, Takeda
ACG Board of Trustees
Oversight of all educational programming content is conducted by the ACG Board of Trustees through a review and approval process. View the ACG Board of Trustees disclosure information by clicking on the link below.
All ACG staff in a position to control the content of a CME activity are required to complete ACG’s COI form annually. As of January 2017, all ACG staff in a position to control CME content have nothing to disclose.